Corvus Pharmaceuticals to Showcase Innovations at Investment Event
![Corvus Pharmaceuticals to Showcase Innovations at Investment Event](https://investorshangout.com/images/blog/ihnews-Corvus%20Pharmaceuticals%20to%20Showcase%20Innovations%20at%20Investment%20Event.jpg)
Corvus Pharmaceuticals Set to Present at Major Investment Conference
BURLINGAME, Calif. — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a notable player in the clinical-stage biopharmaceutical landscape, is excited to announce that its president and CEO, Richard A. Miller, M.D., along with Jeffrey Arcara, the chief business officer, will engage in one-on-one meetings with investors and deliver a comprehensive corporate presentation. This significant event will take place at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9 to 11, 2024.
Event Details and Presentation Insights
The highlight of the event will be Corvus Pharmaceuticals' presentation scheduled for Tuesday, September 10 at 12:00pm ET. Investors and stakeholders will have the opportunity to gain insights into the company’s strategic direction and innovative therapies.
Webcast Availability
For those unable to attend in person, a live webcast of the presentation will be available. Additionally, it will remain accessible for 90 days following the conference, allowing interested parties to catch up on the discourse and insights shared during the event.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is dedicated to pioneering the development of ITK (Interleukin-2-inducible T-cell kinase) inhibition, advancing a new paradigm in immunotherapy for various cancers and immune-related diseases. The company’s lead candidate, soquelitinib, is an oral, investigational, small molecule drug designed to selectively inhibit ITK. This innovation stands to potentially redefine how we approach treatment for some formidable health challenges.
Ongoing Clinical Developments
Aside from soquelitinib, Corvus Pharmaceuticals is actively developing a portfolio of other clinical-stage candidates targeted at treating different indications of cancer. Their commitment to addressing unmet needs in the therapeutic landscape underscores their position as a leader in groundbreaking treatments.
Contact Information for Investors and Media
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
Phone: +1-650-900-4522
Email: llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
Phone: +1-949-903-4750
Email: sseapy@realchemistry.com
Frequently Asked Questions
1. What is the significance of the H.C. Wainwright conference for Corvus Pharmaceuticals?
The conference is a pivotal platform for Corvus to connect with investors and share updates regarding their innovative therapeutic approaches in oncology.
2. Who will be representing Corvus Pharmaceuticals at the event?
Richard A. Miller, M.D., the president and CEO, along with Jeffrey Arcara, Chief Business Officer, will represent the company.
3. What are the expected outcomes from the conference presentation?
The conference presentation aims to provide insights into the company's strategies, product pipeline, and future directions in cancer treatment.
4. How can one access the presentation if they cannot attend?
A live webcast of the presentation will be available on the Corvus website, along with a recording accessible for 90 days post-event.
5. What is Corvus Pharmaceuticals focused on developing?
Corvus is focused on creating novel therapies targeting ITK inhibition to combat a wide range of cancer and immune diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- AI Video Generator Market Expected to Hit USD 2980 Million
- Bird Construction to Host Investor Day, Unveils Strategic Plan
- Cipher Mining Reports Robust August 2024 Operational Results
- NCL Corporation Ltd. Prices $315 Million Senior Notes Offering
- Franklin Resources, Inc. Investigation by Pomerantz Law Firm
- Investigation Launched for WEBTOON Entertainment Investors
- Investigation of iLearningEngines, Inc. Over Securities Issues
- Investigation into Bumble Inc. by Pomerantz Law Firm - BMBL
- Ibotta Inc. Under Investigation for Alleged Securities Fraud
- Investigation Launched into WisdomTree, Inc. - WT Investors
- Pomerantz Law Firm Investigates Liquidia Corporation Investors
- Investigation into Bank of Montreal by Pomerantz Law Firm
- Investigation into Piedmont Lithium Inc. by Pomerantz Law Firm
- Impact of Fed's Rate Cut on RBA: Insights from Citi Economics
- Investigation Alert: Globus Medical, Inc. (NYSE: GMED) Claims
- Zscaler Reports Growth Yet Stock Drops 13% on Outlook
- Credit Rating Agencies Agree to Settle for $49 Million in Penalties
- Russian Stocks Face Decline as Market Conditions Shift
- Investigation Into Claims Against European Wax Center, Inc. EWCZ
- Investigation Into Mineralys Therapeutics, Inc. (MLYS) Claims
- 36Kr Holdings Inc. Earnings Report: Strategies for Growth Ahead
- Investigation Launched into Mynaric AG by Pomerantz Law Firm
- Colombia Stock Market Update: COLCAP Declines Amid Sector Losses
- Mexican Stock Market Experiences Significant Decline Today
- US Stock Market Faces Volatility as September Begins
Recent Articles
- Pomerantz Law Firm Investigates Liquidia Corporation Investors
- Russian Stocks Face Decline as Market Conditions Shift
- Investigation Launched into Mynaric AG by Pomerantz Law Firm
- Insights on Walmart, Merck, and Nike Post-Earnings Review
- Borr Drilling Limited Special General Meeting Announcement
- QIAGEN N.V. Sets Conversion Price for New Convertible Bonds
- ONEOK to Engage at Barclays CEO Energy-Power Conference
- Counterpart Health Partners with The Iowa Clinic for AI Innovation
- Methode Electronics Faces Class Action for Securities Fraud
- Floor Coatings Market Growth Driven by Innovations and Demand
- Forecast for Downward Shift in U.S. Housing Inflation Trends
- First Citizens Bank Secures $145 Million Financing for Linea Energy
- Silicon Valley Reacts to the Unrealized Gains Tax Proposal
- Spartan Capital Securities Celebrates 2024 Summer Interns
- Rheumatoid Arthritis Drugs Market Forecasts for Major Growth
- Everclear Extends Token Lock-Up for Sustainable Community Growth
- Oliveda International Inc. Achieves Daily Sales Milestone
- Israeli Finance Minister Outlines 2025 Budget Amid War Costs
- Brazil Senate Delays Galipolo's Central Bank Confirmation Vote
- Forgd Launches Free Tools for Streamlined Token Launches
- Empower Partnerships Strategic Leadership Appointments Boost Growth
- Sippable Delight: Baileys Cinnamon Churros Cream Liqueur
- Cleartide Unveils Stylish and Efficient Condensate Pumps
- UK Home Prices Expected to Rise, Boosting First-Time Buyer Affordability
- Corporate Profit Challenges: Earnings Outlook for 2025